BODE Index (COPD Prognosis)

Multidimensional prognostic index for COPD based on Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity. Predicts mortality and guides clinical decision-making including transplant evaluation.

Pulmonology PulmonologyEvidence-BasedUpdated 2026-08

Clinical decision-support tool for qualified healthcare professionals. Results are not a diagnosis and should not replace professional clinical judgment.

Clinical Notes

The BODE Index was published by Celli et al. in 2004 (NEJM 350:1005-1012) and validated in a large international cohort. It is a validated multidimensional scoring system that outperforms FEV1 alone for predicting mortality in COPD. The BODE Index has been incorporated into international COPD guidelines (GOLD) as a tool for assessing disease severity and guiding treatment decisions, including lung transplant eligibility.

Calculator Information

Specialty

Pulmonology

📋 Reference Ranges

Normal Range

0–2

Reference ranges for this calculator
Classification	Range
Low risk	0–2
Moderate risk	3–4
High risk	5–6
Very high risk	7–10

What This Calculator Measures

Multidimensional prognostic index for COPD based on Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity. Predicts mortality and guides treatment decisions including transplant evaluation.

How to Use

Enter patient BMI (kg/m²), FEV1 % predicted, mMRC dyspnea grade (0–4), and 6-minute walk distance (meters).
The calculator scores each component and sums to a BODE Index (0–10).
Score 0–2: Low risk (~10% 4-year mortality).
Score 3–4: Moderate risk (~25% 4-year mortality).
Score 5–6: High risk (~50% 4-year mortality).
Score 7–10: Very high risk (~80% 4-year mortality). Consider lung transplant referral.

How the Calculation Works

The BODE index sums four weighted subscores each 0-3: BMI (1 point if 21 kg/m2 or lower, else 0; capped at 1), FEV1 % predicted (0 for >= 65, 1 for 50-64, 2 for 36-49, 3 for < 36), mMRC dyspnea grade (0 for <= 1, 1 for 2, 2 for 3, 3 for 4), and 6-minute walk distance (0 for >= 350 m, 1 for 250-349, 2 for 150-249, 3 for < 150), for a total of 0-10. Higher totals predict greater 4-year mortality.

Variables Explained

Body Mass Index (BMI)

BMI in kg/m2; 21 or lower contributes 1 point to the BMI subscore.

FEV1 % Predicted

FEV1 as a percentage of predicted, contributing 0-3 points across the defined bands.

mMRC Dyspnea Grade

mMRC dyspnea grade (0-4), mapped to 0-3 points.

6-Minute Walk Distance

Six-minute walk distance in meters, contributing 0-3 points across the defined bands.

Interpretation Guide

Higher BODE scores indicate worse prognosis. The BODE Index is superior to FEV1 alone for predicting mortality. Scores ≥7 should prompt consideration of lung transplant referral and advanced care planning.

Clinical Significance

The BODE Index outperforms FEV1 alone for predicting mortality in COPD. It is recommended by GOLD guidelines for comprehensive assessment and has been validated in multiple international cohorts.

When It Is Useful

Stable COPD patients for mortality risk assessment
Guiding treatment intensity and rehabilitation referrals
Evaluating lung transplant candidacy
Tracking disease progression over time

When It Is Not Useful

During acute COPD exacerbations (components may be temporarily worsened)
In patients unable to perform 6-minute walk test
As a sole determinant for treatment decisions (must integrate clinical context)

Common Mistakes

Entering the FEV1 in liters instead of FEV1 percent predicted, which the airflow obstruction subscore requires.
Adding the mMRC grade directly as points, when grades 0-1 both score 0 and grade 4 scores 3 rather than 4.
Performing the assessment during an acute exacerbation, when dyspnea and walk distance temporarily worsen the result.

Limitations

Validated in stable COPD patients; may be less reliable during exacerbations.
6-minute walk test requires proper instruction and supervision.
BMI cutoff may vary in different populations, including elderly patients and different ethnic groups.
Does not account for comorbidities beyond the four measured components.

Worked Example

A 65-year-old COPD patient with BMI 22, FEV1 45%, mMRC grade 3, and 6MWD 200 meters.

Inputs:

bmi: 22

fev1-percent: 45

mmrc-dyspnea: 3

six-minute-walk: 200

Expected Result: BMI score 0 (>21), FEV1 score 2 (36–49%), mMRC score 2 (grade 3), 6MWD score 2 (150–249m). BODE = 0+2+2+2 = 6 (high risk). Intensify therapy and consider pulmonary rehabilitation.

Evidence & References

Source:: Pulmonology
Content updated:: 2026-08

GOLD Report 2024.

References

Celli BR, et al. N Engl J Med. 2004;350(10):1005-1012. (Original validation)
GOLD Report 2024. Global Strategy for COPD. (Clinical guideline)

Frequently Asked Questions

What does the BODE Index measure?

The BODE Index is a composite score (0–10) that combines four validated predictors of mortality in COPD: Body mass index (B), airflow Obstruction (O, measured by FEV1 % predicted), Dyspnea (D, measured by mMRC scale), and Exercise capacity (E, measured by 6-minute walk distance).

What does a high BODE score mean?

A higher BODE score indicates worse prognosis. Scores 0–2 have ~10% 4-year mortality, while scores 7–10 have ~80% 4-year mortality. Scores ≥7 should prompt consideration of lung transplant referral and advanced care planning.

How often should BODE be reassessed?

BODE should be reassessed at least annually in stable COPD patients, and more frequently (every 3–6 months) in patients with moderate-to-severe disease or during exacerbation recovery.

Can BODE Index guide lung transplant decisions?

Yes. A BODE score ≥7 is associated with very high mortality and is one indicator for lung transplant referral. However, transplant decisions involve multiple factors including comorbidities, functional status, and patient preferences.

Is BODE Index validated for all COPD patients?

BODE was validated in stable COPD patients. It may be less reliable during acute exacerbations, in very elderly patients, or in patients with significant comorbidities affecting exercise capacity.

Disclaimer: This calculator is intended for educational and clinical decision support purposes only. BODE Index should be used as part of comprehensive COPD assessment, not as a standalone tool for treatment decisions.